Profile data is unavailable for this security.
About the company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
- Revenue in USD (TTM)522.75m
- Net income in USD-558.99m
- Incorporated2011
- Employees1.28k
- LocationUltragenyx Pharmaceutical Inc60 Leveroni CtNOVATO 94949-5746United StatesUSA
- Phone+1 (415) 483-8800
- Fax+1 (415) 483-8810
- Websitehttps://www.ultragenyx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Edgewise Therapeutics Inc | 0.00 | -115.88m | 3.41bn | 97.00 | -- | 6.67 | -- | -- | -1.53 | -1.53 | 0.00 | 5.45 | 0.00 | -- | -- | 0.00 | -26.88 | -- | -27.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Apogee Therapeutics Inc | 0.00 | -118.49m | 3.57bn | 91.00 | -- | 4.48 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
Alvotech SA | 308.73m | -618.38m | 3.83bn | 999.00 | -- | -- | -- | 12.39 | -2.65 | -2.65 | 1.28 | -2.27 | 0.312 | 1.80 | 3.66 | 309,038.00 | -62.49 | -- | -222.85 | -- | 48.79 | -- | -200.30 | -- | 0.1569 | -0.2323 | 2.04 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
Immunitybio Inc | 1.31m | -597.65m | 3.88bn | 622.00 | -- | -- | -- | 2,966.13 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Rhythm Pharmaceuticals Inc | 112.53m | -261.57m | 4.14bn | 226.00 | -- | 368.84 | -- | 36.77 | -4.31 | -4.31 | 1.86 | 2.49 | 0.3136 | 1.18 | 6.65 | 497,920.30 | -72.15 | -47.21 | -90.85 | -52.84 | 88.61 | -- | -230.11 | -681.38 | 3.34 | -- | 0.417 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
TG Therapeutics Inc | 264.79m | -14.36m | 4.46bn | 300.00 | -- | -- | -- | 16.85 | -0.1067 | -0.1067 | 1.74 | -- | -- | -- | -- | 1,002,992.00 | -- | -62.87 | -- | -80.06 | 88.32 | -- | -5.42 | -405.03 | -- | -0.0259 | -- | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Immunovant Inc | 0.00 | -323.01m | 4.49bn | 207.00 | -- | 10.00 | -- | -- | -2.21 | -2.21 | 0.00 | 3.06 | 0.00 | -- | -- | 0.00 | -79.97 | -- | -92.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
Denali Therapeutics Inc | 0.00 | -427.49m | 4.51bn | 390.00 | -- | 3.42 | -- | -- | -2.76 | -2.76 | 0.00 | 9.17 | 0.00 | -- | -- | 0.00 | -31.77 | -14.98 | -33.76 | -17.71 | -- | -- | -- | -104.50 | -- | -- | 0.0043 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
Ultragenyx Pharmaceutical Inc | 522.75m | -558.99m | 4.65bn | 1.28k | -- | 13.40 | -- | 8.90 | -6.46 | -6.46 | 6.02 | 3.76 | 0.3766 | 1.91 | 6.06 | 409,674.80 | -40.27 | -33.35 | -50.12 | -38.30 | 86.25 | 93.13 | -106.93 | -154.71 | 2.65 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
Alkermes Plc | 1.51bn | 502.58m | 4.67bn | 2.10k | 9.78 | 3.61 | 8.60 | 3.10 | 2.95 | 1.96 | 8.83 | 7.99 | 0.6788 | 1.32 | 4.24 | 716,724.30 | 22.67 | 1.34 | 28.90 | 1.74 | 83.17 | 83.32 | 33.39 | 2.12 | 3.03 | -- | 0.1827 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Biohaven Ltd | 0.00 | -746.61m | 5.26bn | 239.00 | -- | 12.87 | -- | -- | -9.15 | -9.15 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -137.07 | -- | -176.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
Crinetics Pharmaceuticals Inc | 1.39m | -258.54m | 5.42bn | 290.00 | -- | 5.79 | -- | 3,914.07 | -3.77 | -3.77 | 0.0201 | 10.47 | 0.0023 | -- | 0.4157 | 4,775.86 | -41.16 | -42.53 | -44.29 | -45.36 | -- | -- | -18,257.91 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
Arcellx Inc | 155.82m | -40.42m | 5.54bn | 130.00 | -- | 11.52 | -- | 35.55 | -0.7196 | -0.7196 | 2.98 | 8.95 | 0.226 | -- | -- | 1,198,600.00 | -5.86 | -38.82 | -7.56 | -45.41 | -- | -- | -25.94 | -339.38 | -- | -- | 0.022 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Krystal Biotech Inc | 241.52m | 52.37m | 5.74bn | 229.00 | 112.95 | 6.48 | 96.63 | 23.77 | 1.77 | 1.77 | 8.21 | 30.80 | 0.2725 | 1.51 | 4.53 | 1,054,664.00 | 5.91 | -11.50 | 6.33 | -12.01 | 92.55 | -- | 21.68 | -492.85 | 7.76 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 30 Jun 2024 | 9.65m | 10.47% |
Sands Capital Management LLCas of 30 Jun 2024 | 5.35m | 5.81% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 4.47m | 4.85% |
Wellington Management Co. LLPas of 30 Jun 2024 | 4.44m | 4.82% |
RTW Investments LPas of 30 Jun 2024 | 3.26m | 3.54% |
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 2.90m | 3.15% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.70m | 2.93% |
ClearBridge Investments LLCas of 30 Jun 2024 | 2.35m | 2.55% |
Alkeon Capital Management LLCas of 30 Jun 2024 | 2.24m | 2.43% |
Federated Global Investment Management Corp.as of 30 Jun 2024 | 2.11m | 2.29% |